Adult-onset Still's disease with atypical cutaneous manifestations by Narváez García, Francisco Javier et al.
Observational Study Medicine®
OPENAdult-onset Still’s disease with atypical cutaneous
manifestations
Francisco Javier Narváez Garcia, MD, PhDa,
∗
, María Pascual, MDa, Mercè López de Recalde, MDa,
Pablo Juarez, MDa, Isabel Morales-Ivorra, MDa, Jaime Notario, MD, PhDb, Anna Jucglà, MD, PhDb,
Joan M. Nolla, MD, PhDa
Abstract
The diagnosis of adult-onset Still’s disease (AOSD) can be very difﬁcult. There are no speciﬁc tests available, and diagnosis is usually
based on a symptom complex and the well-described typical evanescent rash seen in the majority of patients. However, in recent
years, other atypical cutaneous manifestations of AOSD have been reported. These atypical skin eruptions often present in addition
to the typical evanescent rash but may also be the only skin manifestation, resulting in delayed diagnosis because of under-
recognition.
In this study, we present 3 new cases of AOSD with atypical cutaneous manifestations diagnosed during a 30-year period in our
department and review 78 additional cases previously reported (PubMed 1990–2016). These 81 patients form the basis of the
present analysis.
The overall prevalence of atypical cutaneous manifestations in our AOSD population was 14%. These manifestations may appear
at any time over the course of the disease, and usually occur in patients who have persistent and severe disease, with a considerable
frequency of clinical complications (23%), including serositis, myopericarditis, lung involvement, abdominal pain, neurologic
involvement, and reactive hemophagocytic syndrome.
The most representative and frequent lesion among the nonclassical skin rashes is the development of persistent pruritic papules
and/or plaques. Interestingly, these lesions show a distinctive histological pattern. Other, less frequently observed lesions include
urticaria and urticaria-like eruptions, generalized or widespread non-pruritic persistent erythema, vesiculopustular eruptions, a
widespread peau d’orange appearance of the skin, and edema of the eyelids mimicking dermatomyositis without any accompanying
skin lesion.
The great majority of these patients required medium or high doses of glucocorticoids (including intravenous methylprednisolone
pulse therapy in some cases) and, in nearly 40%, a more potent or maintenance immunotherapy with immunosuppressant drugs
and/or biologic agents (mainly anakinra or tocilizumab) to control or manage symptoms because of a polycyclic or chronic course.
The development of atypical cutaneous manifestations seems to be associated with a potentially worse prognosis, with a mortality
rate reaching 8% primarily because of infectious complications related to immunosuppressive therapy.
In conclusion, the appearance of atypical cutaneousmanifestations is not uncommon in AOSD. Recognition of this clinical variant is
crucial for the early diagnosis of AOSD, as it might imply persistent disease activity and the need for more aggressive treatment.
Abbreviations: AOSD = adult-onset Still’s disease, NSAIDs = nonsteroidal anti-inﬂammatory drugs, SD = standard deviation.
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Adult-onset Still’s disease (AOSD) is an uncommon, acute,
systemic inﬂammatory disease of unknown etiology that is
classically characterized by intermittent high spiking fevers,
arthralgias/arthritis, typical evanescent rash, sore throat, gener-
alized lymphadenopathy, liver dysfunction, and splenomegaly.[1]
Other features less frequently reported include serositis,
myopericarditis, interstitial lung disease, and neurologic involve-
ment.[1] Furthermore, reactive hemophagocytic syndrome is
occasionally seen.[1] Therefore, it is important to make an early
diagnosis. Several classiﬁcation criteria have been proposed,
being the Yamaguchi’s criteria[2] the most commonly used.
However, the clinical presentation of AOSD is heterogeneous,
and the spectrum of differential diagnoses is wide, including
infection, neoplasia, and other autoimmune disorders, which
should be ruled out before the diagnosis of AOSD can be made.[3]
Laboratory markers, particularly the presence of leukocytosis
with neutrophilia and marked hyperferritinemia, are suggestive
of AOSD, but clinicians often rely on the typical evanescent,
salmon-pink, maculopapular eruption to make the diagnosis.[3]
Though an evanescent eruption is the classic cutaneous ﬁnding, a
recent literature has highlighted atypical rashes associated with
AOSD. These atypical cutaneous manifestations often present in
addition to the typical evanescent rash but may also be the only
skin manifestation, resulting in delayed diagnosis because of
under-recognition.
The objective of this study is to describe 3 new cases of AOSD
with atypical skin features and review the clinical spectrum of
atypical cutaneous manifestations described in this disease.2. Patient and methods
2.1. Patient selection
We retrospectively reviewed all patients with AOSD diagnosed
between January 1985 and December 2015 by the Department
of Rheumatology at the Hospital Universitario de Bellvitge
(Barcelona, Spain), a referral tertiary care hospital. Diagnosis of
AOSD was based on the criteria set by Yamaguchi et al,[2] with
special attention being given to the serum ferritin value.[4]
The major criteria are high fever for >1 week, arthalgias for
>2 weeks, neutrophilic leukocytosis (>10,000/mm3 with >80%
of neutrophils), and the typical evanescent rash. Minor criteria
include sore throat, lymphadenopathy and/or splenomegaly, liver
dysfunction, and the absence of rheumatoid factor and
antinuclear antibody. A minimum of 5 criteria, including at
least 2 major criteria, were required for diagnosis, as well as the
exclusion of infections, malignancy, and other rheumatologic
diseases. The recent criteria proposed by Fautrel et al[5] were not
used because most patients were diagnosed before these criteria
were published, and owing to lack of data for glycosylated
ferritin.
Inpatient and outpatient charts were comprehensively
reviewed to obtain clinical, laboratory, and disease course data.
From a total of 21 patients with AOSD, we selected those who
presented with any cutaneous manifestation different from the
typical evanescent rash, excluding dermographism.
In accordance with the guidelines of our institutional ethics
committee, formal approval for this study was not required. The
local ethics committee agreed that the ﬁndings in this report were
based on normal clinical practice and were therefore suitable for
dissemination. Informed patient consent was obtained and
clinical records and patient data were anonymized. This study2was conducted in accordance with the principles of the
Declaration of Helsinki and the International Conference for
Harmonization.2.2. Literature search strategy and selection criteria
Searches were conducted in the PubMed database (including
MEDLINE, National Library of Medicine, and PubMed Central)
for the period between January 1990 and November 2016, using
strategies recommended by the Cochrane handbook. Search
terms included “adult onset Still’s disease,” “cutaneous mani-
festations,” “skin rash,” “persistent,” or “atypical.” Inclusion
criteria included case reports or series reporting speciﬁc
characteristics of an atypical skin eruption in patients fulﬁlling
the diagnostic criteria of Still’s disease proposed by Yamaguchi
et al.[3] Only English, French, Portuguese, and Spanish reports
were considered. The references of the studies obtained were also
examined to identify additional reports.
TheMEDLINE search resulted in 113 articles. The abstracts or
the full text was screened for inclusion and 84 of them were
excluded. The remaining 29 articles were evaluated, together
with 6 additional reports identiﬁed from review of the references.
Therefore, 35 articles were ﬁnally selected for review (32 case
reports and 3 case series) and 78well-documented cases of AOSD
with atypical skin eruptions were identiﬁed.[6–40] Lee et al[6]
reported 28 cases in aggregate form only; 1 of them was
previously accurately described by Yang et al.[24] Nagai et al[18]
also reported 6 patients in aggregate form only.2.3. Statistical analysis
Qualitative variables are reported as frequencies and percentages
and quantitative variables as mean or median ± standard
deviation (SD) and range.3. Results
Among a total of 21 patients with AOSD diagnosed during a
30-year period in our Department, 3 patients (14%) presented
with atypical persistent cutaneous manifestations: 1 case with
persistent refractory urticaria (Fig. 1), 1 case with persistent
pruritic papules and plaques with ﬂagellate erythema-type
appearance (Fig. 2), and 1 case with persistent pruritic plaques
on the chest and concomitantly evanescent urticarial rash (Fig. 3).
Table 1 summarizes the main clinical characteristics and
outcomes of these 3 patients.
Table 2 summarizes the main clinical characteristics and
outcome of the 78 patients obtained from the literature. These 78
cases, together with our 3 patients, form the basis of the present
analysis. Because it is a review of the literature and the series of
Lee et al[6] and Nagai et al[18] reported their cases in aggregate
form only, not all analyzed variables were recorded in all
included cases. Thus, the results (percentages) in each variable
were calculated considering only the number of patients in which
the data were documented.
The global analysis of the 81 patients available for review
provided the following information:3.1. Demographic data
Of the 81 patients, the great majority were women (48/55; 87%)
with ages ranging from 18 to 83 years (median 36 ± 16 years).
Most of the cases (52/81; 64%) were reported from East Asia.
Figure 2. Patient 2: Clinical images of a 52-year-oldHispanicmanwith persistent pruri
Figure 1. Patient 1: Clinical images of a 54-year-old woman with a persistent
urticarial rash on the trunk and limbs as disease onset.
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33.2. Atypical cutaneous lesions reported in association
with AOSD
In the great majority of cases, the atypical skin eruption presented
at the time of disease onset concurrently with systemic symptoms,
or shortly afterward. Rarely, it was the presenting feature of
AOSD preceding the appearance of the classic symptoms of the
disease from a few weeks to 3 years, or it appeared during a
disease ﬂare several months after the initial diagnosis (as late as
29 months). In 57% (46/81) of patients, the atypical cutaneous
lesions presented concurrently with the typical evanescent rash.
The most frequent atypical skin lesions described were the
development of persistent papules and/or plaques (61/81; 75%).
These lesions were usually, but not always, pruritic (53/61; 87%).
Descriptors for the color varied from erythematous or brown in
the majority of cases to, less commonly, violaceous. They may
present with scales or crusts. The most frequent locations were
the trunk (in order of frequency: back, chest, and abdomen) and
the extensor surface of the extremities. This type of eruption often
had a linear conﬁguration, possibly because of the Koebner
phenomenon, thus resembling a ﬂagellate erythema. Other
commonly reported morphologic patterns included urticarial
papules, lichenoid papules, pigmented plaques, prurigo pigmen-
tosa-like, dermatomyositis-like, and lichen amyloidosis-like
rashes. More than 1 morphology or distribution pattern was
observed in several patients.
The dermatomyositis-like eruption was pruritic and tended to
have extensive cutaneous involvement manifesting as erythema-
tous to violaceous or dusky red maculopapules or patches in a
clear photodistribution. In addition, there was erythema and
swelling of the upper eyelids resembling a heliotrope sign as well
as the presence of erythematous maculopapules on the knuckles
of the ﬁngers mimicking Gottron papules. The prurigo
pigmentosa-like eruption manifested as pruritic, erythematous
urticarial to brownish lichenoid papules, which were arranged intic papules and plaqueswith ﬂagellate erythema-type appearance at disease onset.
Figure 3. Patient 3: Clinical images of a 29-year-old Hispanic woman who developed persistent pruritic plaques on the chest (A) and concomitant evanescent
urticarial rash with intermittent high spiking fevers (B and C) during a disease ﬂare 29 months after diagnosis of the disease.
Table 1
Main clinical characteristics and outcome of our patients.
Patient 1 Patient 2 Patient 3
Age, y/Sex 54/F 52/M 29/F
Ethnicity Caucasian Hispanic Hispanic
Fever Yes Yes Yes
Arthralgia/rthritis Yes (polyarthritis) Yes (polyarthritis) Yes (inﬂammatory arthralgias)
Typical evanescent rash No No Yes
Atypical cutaneous rash Persistent urticarial rash
on trunk and limbs as
disease onset
Persistent pruritic papules and
plaques with ﬂagellate
erythema-type appearance
as disease onset
Persistent pruritic plaques on the
chest and concomitant urticarial
evanescent rash that appeared
during a disease ﬂare 29 months
after diagnosis
Sore throat Yes No Yes
Lymphadenopathy No Yes Yes
Hepatomegaly No No No
Splenomegaly No No Yes
Reactive hemophagocytic syndrome No No Yes (2 episodes)
Other clinical manifestations No No Aseptic meningitis and abdominal
pain because of serositis
WBC (3.9–10  103/mm3) /Neutrophilia 16.000 / 76% 14.700 / 90% 14.200 /78%
Ferritin level (30–400 mg/L) 2921 1965 4242
Liver dysfunction tests Yes Yes Yes
Negative RF/ANA Yes Yes Yes
Skin biopsy Superﬁcial perivascular
inﬂammatory cell inﬁltrate
Aggregated necrotic keratinocytes
in the upper half of the epidermis
with a perivascular inﬂammatory
inﬁltrate in the upper and
mid-dermis, without vasculitis
ND
Treatment NSAIDs, antihistamines,
PDN 40 mg/day, MTX
and ﬁnally TCZ
NSAIDs, antihistamines,
PDN 40 mg/day, MTX
and ﬁnally TCZ
IV MP pulses, IV immunoglobulins,
PDN 60 mg/day, CsA and
biologic agents (anakinra:
primary inefﬁcacy; TCZ:
stopped because of infusion
reactions; currently canakimumab)
Follow-up time, mo 52 23 30
Outcome Chronic articular polycyclic
systemic course
Chronic articular polycyclic
systemic course
Polycyclic systemic course
ANA= antinuclear antibodies, CsA= cyclosporine A, IV= intravenous, MP=methylprednisolone, MTX=methotrexate, ND=not done, NSAIDs=nonsteroidal anti-inﬂammatory drugs, PDN=prednisone, RF=
rheumatoid factor, TCZ= tocilizumab, WBC=white blood cell.
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Table 2
Clinical characteristics and outcome of the 78 reported cases with adult-onset Still’s disease and atypical skin rashes.
Variable
Number (%) of patients
in whom these data
were recorded
Results considering only the
number of patients in whom
these data were recorded
Age, y (median ± SD)
∗
46/78 (59%) 35.5±16
Sex (female/male)† 52/78 (67%) 46 (88%)/6 (12%)
Reported ethnicity 78/78 (100%) Taiwanese or east Asian: 52 (67%)
Clinical manifestations 78/78 (100%)
Fever 78 (100%)
Arthralgia/Arthritis 76 (97%)
Sore throat 53 (68%)
Typical evanescent rash 46 (59%)
Lymphadenopathy 44 (56%)
Hepatomegaly/splenomegaly 35 (45%)
Serositis 6 (8%) (pleuritis 4/pericarditis 1/pleuropericarditis 1)
Myopericarditis 2 (3%)
Pneumonitis/Acute respiratory distress syndrome 3 (4%)
Neurologic involvement 2 (3%)
Reactive hemophagocytic syndrome 4 (5%)
Laboratory ﬁndings
Elevated ferritin 75 (96%)
Liver dysfunction tests 59 (76%)
Fulminant hepatitis 1 (1%)
Atypical cutaneous lesions (References) 78/78 (100%)
Persistent papules and plaques 52 (67%) [6–21] (pruritic 46 /non-pruritic or minimal 6)
Persistent papules 4 (5%) [22–25] (pruritic 3)
Persistent (ﬁxed) plaques 3 (4%) [11,26,27] (pruritic 2 /non-pruritic 1)
Urticaria and urticaria-like eruptions 8 (10%) [28–33]
Generalized or widespread persistent erythema 6 (8%) [18,34–36]
Vesiculopustular eruption 2 (3%) [37,38]
Widespread peau d’orange appearance of the skin 1 (1%) [39]
(cutaneous mucinosa).
Angioedema 1 (1%) [40]
Edema of the eyelids mimicking dermatomyositis 1 (1%) [18]
without any accompanying skin lesion
Cutaneous biopsy (skin histology) 67/78 (86%)
Treatment 73/78 (94%)
NSAIDs 39/73 (53%)
Glucocorticoids 68/73 (93%)
Intravenous methylprednisolone pulse therapy 12/73 (16%)
Immunosuppressive agents‡ 26/73 (36%)
MTX 20 / AZA 5 /CsA 4/ HCQ 3 / Otherx 3
Biologic agents‡ 4/73 (5%)
Anakinra 3 / TCZ 1 / Etanercept 1
Intravenous immunoglobulins 1 (1%)
Long-term outcome 72/78 (92%)
Self-limiting or monocyclic systemic disease 12/72 (17%)
Polycyclic systemic or chronic articular polycyclic 54/72 (75%)
systemic disease
Exitus 6/72 (8%)
The results are presented as means or medians ± standard deviations or the number of cases with percentages.
AZA = azathioprine; CsA=cyclosporine A; HCQ=hydroxychloroquine; MTX=methotrexate; NSAIDs=nonsteroidal anti-inﬂammatory drugs, SD= standard deviation.
∗
Excluding 27/28 cases reported by Lee et al[6] in aggregate form only and the 6 cases reported by Nagai et al[18] in aggregate form only.
† Excluding 27/28 cases reported by Lee et al[6].
‡ Some patients received >1 immunosuppressive or biologic agent.
x Other immunosuppressive agents: cyclophosphamide 1, mizoribine, thalidomide 1.
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morphology and distribution of prurigo pigmentosa.
Another frequently reported atypical lesion was urticaria and
urticaria-like eruptions (11/81;14%). With the exception of one
of our patients, all other cases were persistent and refractory,
with poor response to treatment with antihistamines and low
doses of oral corticosteroids. Most of these patients had
dermographism, suggesting that patients in the active stage are5susceptible to urticaria, and some presented with concomitant
angioedema of the eyelids, lips, palms, and soles.
Other skin eruptions less frequently described were generalized
or widespread non-pruritic persistent erythema (6/81; 7%),
which was pigmented in more than half of the cases; more rarely,
vesiculopustular eruptions reported on the hands and feet or
involving the trunk and limbs (2/81; 2.5%); a widespread peau
d’orange appearance of the skin (cutaneous mucinosa) (1/81;
Narváez Garcia et al. Medicine (2017) 96:11 Medicine1%); and edema of the eyelids mimicking dermatomyositis
without any accompanying skin lesion (1/81; 1%).3.3. Other clinical manifestations of AOSD
In addition to the skin eruption and classic symptoms of Still’s
disease (fever, arthralgias/arthritis, and sore throat), 57% (46/81)
of these patients presented with lymphadenopathy, 44% (36/81)
with hepatomegaly and/or splenomegaly, and 77% (62/81) with
liver dysfunction.
Other important clinical manifestations were reported in 20%
of the cases (16/81; 2 patients developed 2 complications)
including serositis (6 patients), myopericarditis (2), lung
involvement (3), abdominal pain (4), and neurologic involvement
(3).
Excluding the 33 patients reported in aggregate form in the
studies of Lee et al[6] and Nagai et al,[18] in the remaining 48 cases
the mean values in the Systemic Score System proposed by
Pouchot et al[41] was 5.41±1.5 (range, 3–9). This score system
assings 1 point to each of 12 manifestations present at the time of
disease onset: fever, typical rash, pleuritis, pneumonitis,
pericarditis, hepatomegaly or abnormal function tests, spleno-
megaly, lymphadenopathy, leukocytosis >15,000/mm3, sore
throat, myalgia, and abdominal pain (maximum score: 12
points). Twenty-one percent of cases (10/48) had a score ≥7.
Reactive hemophagocytic syndromewas reported in 6% (5/81)
patients. In total, 23% (19/81) of patients developed clinical
complications (including reactive hemophagocytic syndrome).3.4. Histopathology
Skin biopsy data were available for 90% (73/81) of patients.
Histopathologically, the most frequently observed pattern (58/
73; 79%) was characterized by singly or aggregated dyskeratotic/
necrotic keratinocytes in the upper layers of the epidermis in
association with a perivascular (and sometimes also interstitial)
inﬂammatory inﬁltrate in the upper and mid-dermis, without
vasculitis. The inﬂammatory inﬁltrate was composed mainly of
lymphocytes and neutrophils, with the occasional presence of
eosinophils. Dermal mucin deposition was sometimes seen.
In the group of patients with persistent papules and/or plaques,
cutaneous biopsy was performed in 59 of 61 patients. This
distinctive pattern was observed in 95% (56/59) of cases: in 51
(96%) of the 53 patients who presented with persistent papules
and plaques, in the 2 patients with persistent plaques in whom the
lesions were biopsied (in 2 patients skin biopsy was not
performed), and in 3 (75%) of the 4 patients with persistent
papules. Of interest, in the 3 patients without this distinctive
histopathology, the lesions were non-pruritic.
In the group of patients with urticaria and urticaria-like
eruptions, skin biopsy data were available in 8 of the 10 patients.
The most frequent ﬁnding in these cases was a superﬁcial dermal
edema with perivascular, and sometimes interstitial, neutrophilic
inﬁltrate, with the occasional presence of lymphocytes and
histiocytes.
In the group of patients with generalized or widespread non-
pruritic persistent erythema, a cutaneous biopsy was performed
in 3 of the 6 cases. In 1 patient with persistent pigmented
eruption, a skin biopsy showed the distinctive pattern observed in
patients with persistent papules and/or plaques. In the remaining
2 cases, a biopsy showed a moderate perivascular mononuclear
cell inﬁltration in the edematous upper-mid-dermis, with the
occasional presence of neutrophils. Finally, in the 2 cases with6vesiculopustular eruption, a skin biopsy showed epidermal
spongiosis and signiﬁcant edema and mononuclear inﬁltration in
the upper and mid-dermis.3.5. Treatment
Information about treatment was available in 76 of the 81
patients. The great majority (71/76; 93%) of patients were
treated with glucocorticoids, usually (69/76; 91%) of medium or
high doses (initial doses ≥30mg/daily of prednisone or equiva-
lent). Seventeen percent of patients (13/76) received intravenous
methylprednisolone pulse therapy (1g daily for 3 days), followed
by oral corticosteroids.
In 38% (29/76) of patients, immunosuppressive agents were
used in conjunction with steroids from the initiation of treatment,
or when the patient failed to improve. The most frequently used
were methotrexate (22 cases), azathioprine (5), and cyclosporine
A (4).
Concomitant biologic therapy was employed as a rescue
treatment in refractory cases (7/76; 9%), with good efﬁcacy and
safety proﬁle. The biologic agents used were anakinra (in 4 cases,
effective only in 3), tocilizumab (3 cases), canakimumab (1 case),
and etanercept (in 1 case, with primary inefﬁcacy). Intravenous
immunoglobulin was administered in 2 patients (3%) with
reactive hemophagocytic syndrome.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs), alone or
in combination with glucocorticoids, were employed in 54%
(41/76) of patients. Information about the duration of applied
treatment, particularly with respect to glucocorticoid regimen
and tapering, was not included in the considered articles.3.6. Outcome
Information about follow-up was available for 75 of the 81
patients. Of the 75 patients, 12 (16%) had a self-limiting or
monocyclic systemic disease[42]. Six patients (8%) died: 3 within
the ﬁrst 3 months after diagnosis of the disease, 1 within
4 months, and 2 within a year of diagnosis. Four of these deaths
were because of sepsis following immunosuppressive therapy.
One patient died because of disease (she presented with high fever
and pleural effusion at the disease onset and died shortly
thereafter of respiratory failure despite immunosuppressive
therapy), and 1 died shortly after the diagnosis of AOSD from
unrelated causes.
The remaining patients (57/75; 76%%) had a polycyclic
systemic or chronic articular polycyclic systemic disease[42] with
persistent but temporarily resolved or controlled symptoms.4. Discussion
The diagnosis of AOSD can be very difﬁcult. There are no speciﬁc
tests and reliance is usually placed on a symptom complex and the
well-described typical rash seen in most patients. However, in
recent years, other atypical cutaneous manifestations of AOSD
have been reported; these rare presentations are not routinely
recognized[6–38] Atypical cutaneous features often present in
addition to the typical evanescent rash, but in 43% of the cases
they are the only skin manifestation.[6,8,11,14,15,17,25,28–33,37,38]. A
delayed diagnosis in these cases is still common, as the cutaneous
lesions are often misdiagnosed as an allergic reaction to drugs,
usually NSAIDs prescribed for joint symptoms or fever.
The appearance of atypical skin features in AOSD is not
uncommon, with a prevalence of 14% according to our
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over the course of the disease. In the great majority of cases, the
atypical skin eruption presented at the time of disease onset
concurrently with systemic symptoms, or shortly afterward.
Rarely, cutaneous lesions were the presenting feature of AOSD
preceding the appearance of the classic symptoms of the
disease[9,13,23,29,30] or appeared during a ﬂare several months
after the diagnosis.[17,26,37]
The most representative and frequent lesion among the
nonclassical skin rash is the development of persistent pruritic
papules and/or plaques.[6–27] Descriptors for the color of these
lesions varied from erythematous or brown in the majority of
cases to, less commonly, violaceous. Theymay present with scales
or crusts, and usually involve the back, upper chest, abdomen,
and extensor surface of the extremities. This type of eruption
often has a linear conﬁguration, possibly because of the Koebner
phenomenon, thus resembling a ﬂagellate erythema.[6–19] Other
commonly reported morphologic patterns include urticarial
papules, lichenoid papules, pigmented plaques, prurigo pigmen-
tosa-like, dermatomyositis-like, and lichen amyloidosis-like
rashes.[6–18,20–27] More than 1 morphology or distribution
pattern was observed in several patients.[6–27] Interestingly,
persistent pruritic papules and plaques show a distinctive
histological pattern characterized by singly or aggregated
dyskeratotic/necrotic keratinocytes in the upper layers of the
epidermis in association with a perivascular inﬂammatory
inﬁltrate in the upper and mid-dermis.[6–13,15–20,23–27,43] Dermal
mucin deposition is sometimes seen.
Other nonclassical skin lesions less frequently observed include
urticaria and urticaria-like eruptions,[28–34] generalized or
widespread non-pruritic persistent erythema,[18,35–37] vesiculo-
pustular eruptions,[38,39] a widespread peau d’orange appearance
of the skin (cutaneous mucinosa),[40] and edema of the eyelids
mimicking dermatomyositis without any accompanying skin
lesion.[18] In cases of urticaria/urticaria-like eruptions and
generalized (widespread) nonpruritic persistent erythema, biopsy
specimens reveal a nonspeciﬁc slight to moderate inﬂammatory
inﬁltrate in the upper dermis, similar to that observed in biopsies
of the typical evanescent skin rash.[1–3,43] Thus, a skin biopsy of
atypical eruptions is recommended (specially in patients who do
not yet fulﬁll the Yamaguchi criteria) because the histologic
features and the previously discussed distinctive pattern can be
considered to be highly suggestive of AOSD.
Additionally, association or co-occurrence of alopecia, acne-
like lesions, erythema chronicum migrans, cutaneous polyarter-
itis nodosa, cutaneous vasculitis associated with mixed cryoglo-
bulinemia, and Sweet’s syndrome has been reported,[44–47]
although it is not clear in these cases if the association is casual
or a coincidence.
The great majority of patients with AOSD and atypical
cutaneous lesions had persistent and severe disease, with
a considerable frequency (23%) of clinical complications,
including serositis, myopericarditis, lung involvement,
abdominal pain, neurologic involvement, and reactive hemo-
phagocytic syndrome[7,10,16–19,24,29,30,31,37]. Thus,most patients
required medium or high doses of glucocorticoids (including
intravenous methylprednisolone pulse therapy in some cases)
and, in nearly 40%, a more potent or maintenance
immunotherapy consisting of immunosuppressant drugs (in-
cluding methotrexate, azathioprine, cyclosporine A, and
hydroxychloroquine)[6,8–10,12,15,16,18–20,24,25,28,29,31,34,39,40] and/
or biologic agents (mainly anakinra or tocilizumab)[8,10,15,21] to
control or manage symptoms because they had an intermittent/7polycyclic or chronic systemic course.Thedevelopmentof atypical
cutaneousmanifestations seems to be associatedwith a potentially
worse prognosis (especially those with persistent pruritic papules
and plaques with dermatomyositis-type appearance), with a
mortality rate that reached 8% primarily because of infectious
complications related to the immunosuppressive therapy[6,10,24].
In this sense, 21% of these patients had a score ≥7 at the time of
disease onset in the Systemic Score System proposed by Pouchot
et al.[41] This score system has a proven predictive value and a
score ≥7.0 has demonstrated a strong prognostic impact in
identifying patients at risk of AOSD-related death.[48]
In addition, 96% of patients with atypical cutaneous
manifestations presented hyperferritinemia. During AOSD,
persistent high serum levels of ferritin may be observed; it is
an iron storage protein composed of 24 subunits, heavy (H)
subunits and light (L) subunits. The ferritin enriched in L subunits
(L-ferritin) and the ferritin enriched in H subunits (H-ferritin)
may be observed in different tissues.[49] Recently, Ruscitti et al[49]
have demonstrated an increased skin expression of H-ferritin in
the biopsies obtained from persistent cutaneous lesions of AOSD
patients, associated with a strong inﬁltrate of CD68+/H-ferritin+
cells. This ﬁnding seems to have clinical implications as according
to their ﬁndings there is a correlation between both, the tissue H-
ferritin levels and the CD68+/H-ferritin+ cells, with the severity of
the clinical picture and the multi-visceral involvement of the
disease.
In conclusion, the appearance of atypical cutaneous manifes-
tations is not uncommon in AOSD. Recognition of this clinical
variant is crucial for the early diagnosis of AOSD, as it might
imply persistent disease activity and the need for more aggressive
treatment. However, in interpreting the results of our study, we
cannot ignore the pitfalls inherent in any systematic review
including the relatively small number of identiﬁed patients, the
retrospective design, and incomplete follow-up data in some
cases. More studies are needed to conﬁrm these results.References
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